Cargando…

Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)

Background: Health claims regarding the cholesterol-lowering effect of soluble fiber from oat products, approved by food standards agencies worldwide, are based on a diet containing ≥3 g/d of oat β-glucan (OBG). Given the number of recently published randomized controlled trials (RCTs), it is import...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitehead, Anne, Beck, Eleanor J, Tosh, Susan, Wolever, Thomas MS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Nutrition 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394769/
https://www.ncbi.nlm.nih.gov/pubmed/25411276
http://dx.doi.org/10.3945/ajcn.114.086108
_version_ 1783229772942278656
author Whitehead, Anne
Beck, Eleanor J
Tosh, Susan
Wolever, Thomas MS
author_facet Whitehead, Anne
Beck, Eleanor J
Tosh, Susan
Wolever, Thomas MS
author_sort Whitehead, Anne
collection PubMed
description Background: Health claims regarding the cholesterol-lowering effect of soluble fiber from oat products, approved by food standards agencies worldwide, are based on a diet containing ≥3 g/d of oat β-glucan (OBG). Given the number of recently published randomized controlled trials (RCTs), it is important to update the findings of previous meta-analyses. Objective: The objective was to quantify the effect of ≥3 g OBG/d on serum cholesterol concentrations in humans and investigate potential effect modifiers. Design: A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/d with an appropriate control. Systematic searches were undertaken in PubMed, AGRICOLA, and Scopus between 1 January 1966 and 6 June 2013, plus in-house study reports at CreaNutrition AG. Studies were assessed with regard to inclusion/exclusion criteria, and data were extracted from included studies by reviewers working independently in pairs, reconciling differences by consensus. Estimates of the mean reduction in serum cholesterol from baseline between the OBG and control diets were analyzed by using random-effects meta-analysis models and meta-regression. Results: OBG in doses of ≥3 g/d reduced low-density lipoprotein (LDL) and total cholesterol relative to control by 0.25 mmol/L (95% CI: 0.20, 0.30; P < 0.0001) and 0.30 mmol/L (95% CI: 0.24, 0.35; P < 0.0001), respectively, with some indication of heterogeneity (P = 0.13 and P = 0.067). There was no significant effect of OBG on high-density lipoprotein (HDL) cholesterol or triglycerides and no evidence that dose (range across trials: 3.0–12.4 g/d) or duration of treatment (range: 2–12 wk) influenced the results. LDL cholesterol lowering was significantly greater with higher baseline LDL cholesterol. There was a significantly greater effect for both LDL and total cholesterol in subjects with diabetes compared with those without (although based on few studies). Conclusions: Adding ≥3 g OBG/d to the diet reduces LDL and total cholesterol by 0.25 mmol/L and 0.30 mmol/L, respectively, without changing HDL cholesterol or triglycerides.
format Online
Article
Text
id pubmed-5394769
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Society for Nutrition
record_format MEDLINE/PubMed
spelling pubmed-53947692017-04-21 Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4) Whitehead, Anne Beck, Eleanor J Tosh, Susan Wolever, Thomas MS Am J Clin Nutr Lipids Background: Health claims regarding the cholesterol-lowering effect of soluble fiber from oat products, approved by food standards agencies worldwide, are based on a diet containing ≥3 g/d of oat β-glucan (OBG). Given the number of recently published randomized controlled trials (RCTs), it is important to update the findings of previous meta-analyses. Objective: The objective was to quantify the effect of ≥3 g OBG/d on serum cholesterol concentrations in humans and investigate potential effect modifiers. Design: A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/d with an appropriate control. Systematic searches were undertaken in PubMed, AGRICOLA, and Scopus between 1 January 1966 and 6 June 2013, plus in-house study reports at CreaNutrition AG. Studies were assessed with regard to inclusion/exclusion criteria, and data were extracted from included studies by reviewers working independently in pairs, reconciling differences by consensus. Estimates of the mean reduction in serum cholesterol from baseline between the OBG and control diets were analyzed by using random-effects meta-analysis models and meta-regression. Results: OBG in doses of ≥3 g/d reduced low-density lipoprotein (LDL) and total cholesterol relative to control by 0.25 mmol/L (95% CI: 0.20, 0.30; P < 0.0001) and 0.30 mmol/L (95% CI: 0.24, 0.35; P < 0.0001), respectively, with some indication of heterogeneity (P = 0.13 and P = 0.067). There was no significant effect of OBG on high-density lipoprotein (HDL) cholesterol or triglycerides and no evidence that dose (range across trials: 3.0–12.4 g/d) or duration of treatment (range: 2–12 wk) influenced the results. LDL cholesterol lowering was significantly greater with higher baseline LDL cholesterol. There was a significantly greater effect for both LDL and total cholesterol in subjects with diabetes compared with those without (although based on few studies). Conclusions: Adding ≥3 g OBG/d to the diet reduces LDL and total cholesterol by 0.25 mmol/L and 0.30 mmol/L, respectively, without changing HDL cholesterol or triglycerides. American Society for Nutrition 2014-12 2014-10-15 /pmc/articles/PMC5394769/ /pubmed/25411276 http://dx.doi.org/10.3945/ajcn.114.086108 Text en © 2014 American Society for Nutrition This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/license/) that permit unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Lipids
Whitehead, Anne
Beck, Eleanor J
Tosh, Susan
Wolever, Thomas MS
Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)
title Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)
title_full Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)
title_fullStr Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)
title_full_unstemmed Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)
title_short Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)
title_sort cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials(1)(2)(3)(4)
topic Lipids
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394769/
https://www.ncbi.nlm.nih.gov/pubmed/25411276
http://dx.doi.org/10.3945/ajcn.114.086108
work_keys_str_mv AT whiteheadanne cholesterolloweringeffectsofoatbglucanametaanalysisofrandomizedcontrolledtrials1234
AT beckeleanorj cholesterolloweringeffectsofoatbglucanametaanalysisofrandomizedcontrolledtrials1234
AT toshsusan cholesterolloweringeffectsofoatbglucanametaanalysisofrandomizedcontrolledtrials1234
AT woleverthomasms cholesterolloweringeffectsofoatbglucanametaanalysisofrandomizedcontrolledtrials1234